Our Team

We’ve brought together a collaborative and patient-focused group of physicians, scientists and seasoned business leaders.


Eboo Versi, MD PhD

CEO, Chairman and Founder
Dr. Versi is the CEO and founder of DMK Pharmaceuticals. He has over 30 years of experience as a physician, surgeon, academic, teacher, entrepreneur, investor, and senior executive. He is the inventor of several patents, and owns over thirty U.S. and international patents under the Versi Group and its licensees. Dr. Versi has served as a pharmaceutical executive at several large (Pfizer, Astellas) and small (Pliva, Mt Cook) companies in a medical capacity culminating as Chief Medical Officer, and head of drug development. Dr. Versi received his Masters and Doctorate from Oxford University and Medical Degree from Cambridge University in the UK.

Neil Frazer, MD

Chief Medical Officer
Dr. Frazer is the Chief Medical officer, and co-founder of DMK Pharmaceuticals. He has over 30 years of experience in managing pharmaceutical product development programs. He has participated in over thirty drug and device development initiatives, leading to successful submissions to US and global regulatory authorities. He strongly believes in working with practicing clinicians, whose key aim is to help their patients achieve a better quality of life through use of existing and innovative therapies. Dr. Frazer holds a B.Sc. and MB.ChB (Medical Degree) from the University of Edinburgh Medical School, and completed Fellowships at the Royal College of Anaesthetists and Royal College of Physicians.

Bina Julian, PhD

Director of Research Operations
Dr. Bina Julian is the Director of Research Operations of DMK Pharmaceuticals. She has spent the last 15 years advancing pharmaceutical research and innovation at Pfizer, the Broad Institute of Harvard and MIT, Tufts Medical Center and Versi Group companies (DMK, Dina, Opus). Dr. Julian holds Master of Engineering and Bachelor of Science degrees in biomedical engineering from Cornell University, and a PhD in Pharmacology and Experimental Therapeutics from Tufts Graduate School of Biomedical Sciences.

Kevin Statz, MBA

Chief Commercial Officer
Mr. Statz has 25 years of diverse commercial biopharmaceutical experience in the specialty space, which includes new product planning and multiple product launches. He has held leadership positions at Anika, Alkermes and Collegium, building key commercial capabilities including distribution, sales operations, managed markets and trade, pricing, Payer, Physician and GPO contracting, all go-to-market strategies, and developing field sales capabilities. He has led marketing and strategy for multiple Brands, across HCP, Managed Markets & Trade, Government Affairs, LTC & Hospital. Mr. Statz holds Bachelor of Science degrees in Biology and Biochemistry from Florida State University, as well as an MBA from MIT Sloan School of Management.

Meera Desai, PhD

VP Business Development
Dr. Desai has over 15 years of pharmaceutical industry experience in drug development and commercialization of products in multiple therapeutic areas. Over her career, she has held positions of increasing responsibility at AcelRx Pharmaceuticals, Novartis, Nektar Therapeutics, and Johnson & Johnson/ALZA Corporation. Dr. Desai has extensive Business and Corporate Development experience negotiating and executing licensing deals valued at over $600 Million, managing complex alliances and supporting the fundraising, financing, and investor relations efforts for small Biotechs. Dr. Desai holds a Bachelor of Science degree in Chemistry from Drew University and a Ph.D. in Analytical Chemistry from Iowa State University.



Opioid Use Disorder Expert

Academic and entrepreneur with long standing expertise in opioid clinical trials. National key opinion leader with 75+ scientific publications


Pain Management and Clinical Trial Expert
Anesthesiologist with 50+ scientific publications, Lead author on Trevena papers on safe approach to pain management


Clinical Urology Expert

World renowned academic urogynecologist, ground-breaking research into overactive bladder with 200+ scientific publications


Parkinson’s Disease Expert

Developed Gold Standard non-human primate model of PD with 200+ scientific publications, 25 years of expertise in developing PD treatments with focus on neuropeptide analogs


Business Strategy Advisor

Serial biotech entrepreneur and seasoned venture-backed, PE- backed and public company officer


Business & Financial Strategy Advisor
Biopharma executive and public company director with more than 25 years in healthcare, finance and capital markets


Business Advisor

Life sciences executive and public company director with more than 18 years of experience; doctorate in Biochemistry & Molecular Pharmacology from Harvard University

Interested in learning more?

Contact Us